Press Releases
November 22, 2019
VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting
November 14, 2019
VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
November 11, 2019
VBI Vaccines to Present Initial Phase 1/2a Part B Data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
November 6, 2019
VBI Vaccines Announces Third Quarter 2019 Financial Results and Provides Corporate Update
October 24, 2019
VBI Vaccines to Present New Immuno-Oncology Data at the World Vaccine Congress Europe 2019
September 26, 2019
VBI Vaccines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 19, 2019
VBI Vaccines Announces Pricing of $35 Million Public Offering
September 18, 2019
VBI Vaccines Announces Proposed Public Offering of Common Shares
September 5, 2019
VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference
August 9, 2019
VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update
July 29, 2019
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
June 20, 2019
VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
June 17, 2019
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
June 16, 2019
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
May 1, 2019
VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update
April 17, 2019
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
February 25, 2019
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
February 7, 2019
VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients
January 16, 2019